Research output per year
Research output per year
Personal profile
Research interests
The overall goal of our research program is “Precision Medicine for Prostate Cancer: Developing novel therapeutics to prevent metastasis by targeting critical transcriptional networks”. The goal is to identify and characterize novel epigenetic readers/modifiers/transcription factors promoting drug resistance and metastasis of prostate cancers (PC). We have identified key transcription factor (TF) regulated networks driving proliferation of metastatic PCs. These networks serve as an important quantitative readout for TF functionality in the clinical space. Working in collaboration with Medicinal Chemists and Structural Biologists, we have recently identified several novel small molecule epigenetic inhibitors that have the potential to inhibit the expression of the TF, its networks and inhibit the growth of metastatic PCs. The eventual goal is to advance these biomarkers and novel therapeutics into clinical trials.
Fingerprint
Dive into the research topics where Kiran Mahajan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer
Nguyen, D. T., Yang, W., Renganathan, A., Weimholt, C., Angappulige, D. H., Nguyen, T., Sprung, R. W., Andriole, J., Kim, E. H., Mahajan, N. P. & Mahajan, K., Sep 15 2022, In: Clinical Cancer Research. 28, 18, p. 4131-4145 15 p.Research output: Contribution to journal › Article › peer-review
-
Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting
Sawant, M., Mahajan, K., Renganathan, A., Weimholt, C., Luo, J., Kukshal, V., Jez, J. M., Jeon, M. S., Zhang, B., Li, T., Fang, B., Luo, Y., Lawrence, N. J., Lawrence, H. R., Feng, F. Y. & Mahajan, N. P., Jun 15 2022, In: Science translational medicine. 14, 649, eabg4132.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance
Sridaran, D., Chouhan, S., Mahajan, K., Renganathan, A., Weimholt, C., Bhagwat, S., Reimers, M., Kim, E. H., Thakur, M. K., Saeed, M. A., Pachynski, R. K., Seeliger, M. A., Todd Miller, W., Feng, F. Y. & Mahajan, N. P., Dec 2022, In: Nature communications. 13, 1, 6929.Research output: Contribution to journal › Article › peer-review
Open Access -
Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance
Ghildiyal, R., Sawant, M., Renganathan, A., Mahajan, K., Kim, E. H., Luo, J., Dang, H. X., Maher, C. A., Feng, F. Y. & Mahajan, N. P., Jan 1 2021, In: Cancer research. 82, 1, p. 155-168 14 p.Research output: Contribution to journal › Article › peer-review
15 Scopus citations -
ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Kim, E. H., Cao, D., Mahajan, N. P., Andriole, J. & Mahajan, K., Sep 1 2020, In: NAR Cancer. 2, 3Research output: Contribution to journal › Review article › peer-review
Open Access16 Scopus citations